SiliconBeat

Remember VaxGen, the South San Francisco firm that won an $877.5 billion federal contract in 2004 to make an anthrax vaccine only to have the money yanked away two years later when it missed a deadline for testing the vaccine?

The poor company has been on the skids ever since. It laid off most of its workforce. And when it tried to merge with its neighbor, Raven biotechnologies, it had to drop the idea last year after some of its major stockholders objected.

Now, what’s left of VaxGen is in beef with its landlord. In a recent filing with the U.S. Securities and Exchange Commission, VaxGen said ts landlord is trying to terminate VaxGen’s lease at 349 Oyster Point Boulevard.

How far the once-high flying company has fallen.